Factors Influencing Regulatory Decision-Making in Signal Management: Analysis Based on the Signals Identified from the FAERS
- PMID: 33721283
- DOI: 10.1007/s43441-021-00265-0
Factors Influencing Regulatory Decision-Making in Signal Management: Analysis Based on the Signals Identified from the FAERS
Abstract
Purpose: This study aimed to identify factors that influence the decision to take safety regulatory actions in routine signal management based on spontaneous reports. For this purpose, we analyzed the safety signals identified from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and related information.
Method: From the signals that the FDA identified in the FAERS between 2008 1Q and 2014 4Q, we selected 216 signals for which regulatory action was or was not taken. Characteristics of the signals were extracted from the FAERS quarterly reports that give information about what signals were identified from the FAERS and what actions were taken for them, and the FAERS data released in the same quarter when the signal was published. Univariate and multivariable logistic regression analysis was used to assess the relationship between the characteristics of each of the signals and the decision on regulatory action.
Result: As a result of the univariate logistic regression analysis, we selected 5 factors (positive rechallenge, number of cases accumulated in the last one-year period before the signal indication, previous awareness, serious outcome, risk for special populations) to include in the multivariable logistic regression model (p < 0.2). The multivariate logistic regression analysis showed that the number of cases accumulated in the last one-year period before the signal indication and previous awareness were associated with the regulatory action (p < 0.05).
Conclusion: The present study showed that number of cases accumulated in the last one-year period before the signal indication and previous awareness potentially associated with the United States regulatory action. When assessing safety signals, we should be careful of the adverse events with a large number of cases accumulated rapidly in a short period. In addition, we should pay attention to new information on not only unknown risks but also previously identified and potential risks.
Keywords: Pharmacovigilance; Regulatory actions; Signal management; Spontaneous reports.
Similar articles
-
Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.BMJ. 2022 Oct 5;379:e071752. doi: 10.1136/bmj-2022-071752. BMJ. 2022. PMID: 36198428 Free PMC article.
-
Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.Drug Saf. 2013 Dec;36(12):1169-78. doi: 10.1007/s40264-013-0116-9. Drug Saf. 2013. PMID: 24178291
-
Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.Clin Ther. 2021 Feb;43(2):380-395. doi: 10.1016/j.clinthera.2020.12.011. Epub 2021 Jan 24. Clin Ther. 2021. PMID: 33504449
-
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.Drug Saf. 2018 Apr;41(4):357-361. doi: 10.1007/s40264-017-0622-2. Drug Saf. 2018. PMID: 29196988 Review.
-
Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS).J Allergy Clin Immunol Pract. 2021 Feb;9(2):819-829.e2. doi: 10.1016/j.jaip.2020.09.021. Epub 2020 Sep 28. J Allergy Clin Immunol Pract. 2021. PMID: 32992044 Free PMC article. Review.
Cited by
-
Signals of Adverse Drug Reactions Communicated by Pharmacovigilance Stakeholders: A Scoping Review of the Global Literature.Drug Saf. 2023 Feb;46(2):109-120. doi: 10.1007/s40264-022-01258-0. Epub 2022 Dec 5. Drug Saf. 2023. PMID: 36469249 Free PMC article.
References
-
- Roger AS. Adverse drug events: identification and attribution. Drug Intell Clin Pharm. 1987;21:915–20. - DOI
-
- Sharrar RG, Dieck GD. Monitoring product safety in the postmarketing environment. Ther Adv Drug Saf. 2013;4(5):211–9. - DOI
-
- ICH Harmonised Tripartite Guideline Pharmacovigilance Planning E2E Recommended for Adoption at Step 4 of the ICH Process on 18 November 2004.
-
- Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions. JAMA. 1999;281(9):825–9. - DOI
-
- Moore TJ, Singh S, Furberg CD. The FDA and new safety warnings. Arch Intern Med. 2012;172(1):78–80. - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials